Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$297.78 USD

297.78
4,621,828

-10.03 (-3.26%)

Updated Feb 6, 2025 04:00 PM ET

After-Market: $299.03 +1.25 (0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.30%
2Buy18.13%
3Hold9.74%
4Sell5.28%
5Strong Sell2.72%
S&P50011.39%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business impact of the Chinese investigations remains minor.

The Zacks Analyst Blog Highlights Amgen, CRISPR, Moderna, Sarepta and Vertex

Amgen, CRISPR, Moderna, Sarepta and Vertex are included in this Analyst Blog.

Company News for Feb 6, 2025

Companies In The News Are:AMGN, PRU, ATO, SPG.

Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval

REGN and AMGN are in the spotlight this week on fourth-quarter earnings release.

AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold

AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity candidate, AMG 513.

Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Amgen (AMGN) Q4 Earnings and Revenues Surpass Estimates

Amgen (AMGN) delivered earnings and revenue surprises of 5.57% and 2.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb

Merck, Pfizer, Eli Lilly, Amgen and Bristol Myers Squibb are included in this Analyst Blog.

Mark Vickery headshot

Markets React to Softening Trade Tariff Policy

An almost immediate retraction of a 25% tariff on imported goods from Mexico prodded this relief trade.

Sweta Killa headshot

Dow Logs Best January Since 2019: 5 Best Stocks in the ETF

Dow Jones emerges stronger than the other indices, logging the best January since 2019. Let's look at the five stocks that drove the rally.

Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts?

Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter 2024 results later this week.

Ahan Chakraborty headshot

Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Kinjel Shah headshot

Eli Lilly Stock Before Q4 Earnings: To Buy or Not to Buy?

Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.

Sundeep Ganoria  headshot

Are These 5 Biotech Stocks Set to Beat Q4 Earnings Estimates?

Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

The Zacks Analyst Blog Highlights Amgen, Cencora, Humana and Ardent Health

Amgen, Cencora, Humana and Ardent Health are included in this Analyst Blog.

Regeneron to Report Q4 Earnings: Is a Beat in the Cards?

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter 2024 results soon.

Curious about Amgen (AMGN) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Amgen (AMGN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

Kaibalya Pravo Dey headshot

4 Healthcare Stocks Poised to Crush Q4 Earnings Estimates

Rising patient volumes, technological advancements, rate hikes and other factors are likely to have benefited healthcare players during Q4. Companies like AMGN, COR, HUM and ARDT are likely to outperform.

Here's Why Amgen (AMGN) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?

Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Amgen (AMGN) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amgen (AMGN) Stock Dips While Market Gains: Key Facts

The latest trading day saw Amgen (AMGN) settling at $280.30, representing a -0.94% change from its previous close.